Company intelligence / Profile preview

Shanghai Semrod Biotechnology

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Semrod Biotechnology is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to the discovery and development of innovative peptide-based therapeutics. The company primarily focuses on metabolic diseases, including obesity, type 2 diabetes, and metabolic-associated steatohepatitis (MASH), as well as oncology. Semrod utilizes a proprietary peptide optimization platform to design multi-target agonists with improved efficacy and safety profiles. Its lead candidate, SRD-001, is a triple agonist targeting GLP-1, GIP, and glucagon receptors currently in clinical development.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: PeptidesBiologic
Industry: Biotech

Beyond the preview

Go deeper on Shanghai Semrod Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Semrod Biotechnology.

Explore the full profile